Biocon Ltd - 16 Sep 2024 Form 4 Insider Report for Bicara Therapeutics Inc. (BCAX)

Reporting relationship: 10%+ Owner
Issuer ticker: BCAX
Reported as of: 16 Sep 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Sep 2024, 16:39:07 UTC
Prior SEC filing: 12 Sep 2024
Source filing: View source filing
Reporting owner signature: BIOCON LIMITED, By: /s/ Kiran Mazumdar-Shaw, Title: Executive Chairperson

Key filing fact

Biocon Ltd filed Form 4 for Bicara Therapeutics Inc. (BCAX) on 16 Sep 2024.

Key facts

This page summarizes Biocon Ltd's Form 4 filing for Bicara Therapeutics Inc. (BCAX).
4 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 16 Sep 2024, 16:39.

Change

Previous filing in this sequence was filed on 12 Sep 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BCAX transaction

Common Stock

Conversion of derivative security

Transaction value: $0
Shares: +4,327,365
Change %: +3738%
Price: $0.000000
Shares after: 4,443,122
Date: 16 Sep 2024
Ownership: By Biocon Limited
Footnotes: F1, F2

BCAX transaction

Common Stock

Conversion of derivative security

Transaction value: $0
Shares: +1,080,775
Change %
Price: $0.000000
Shares after: 1,080,775
Date: 16 Sep 2024
Ownership: By Biocon Pharma Inc.
Footnotes: F1, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BCAX transaction Derivative

Series Seed Redeemable Convertible Preferred Stock

Conversion of derivative security

Transaction value: $0
Shares: -40,000,000
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 16 Sep 2024
Ownership: By Biocon Limited
Underlying class: Common Stock
Underlying amount: 4,327,365
Exercise price
Footnotes: F1, F2

BCAX transaction Derivative

Series Seed Redeemable Convertible Preferred Stock

Conversion of derivative security

Transaction value: $0
Shares: -9,990,144
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 16 Sep 2024
Ownership: By Biocon Pharma Inc.
Underlying class: Common Stock
Underlying amount: 1,080,775
Exercise price
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Upon the closing of the Issuer's initial public offering, each share of Series Seed Redeemable Convertible Preferred Stock (the "Preferred Stock") automatically converted into Common Stock on a 9.2435-to-one basis without payment of consideration. The Preferred Stock had no expiration date.

Footnote F2

Shares held by Biocon Limited ("Biocon Ltd"). Kiran Mazumdar-Shaw is the managing member of Biocon Ltd. Each of the Reporting Persons and Ms. Mazumdar-Shaw disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any Reporting Person is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.

Footnote F3

Shares held by Biocon Pharma Inc. ("Biocon Pharma"). Kiran Mazumdar-Shaw is the managing member of Biocon Pharma. Each of the Reporting Persons and Ms. Mazumdar-Shaw disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any Reporting Person is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.